OpenAI CEO Sam Altman’s new brain-computer interface startup, Merge Labs, is being spun out of the Los Angeles–based nonprofit Forest Neurotech, according to a source with direct knowledge of the ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Altman taps a leading researcher for his brain-computer interface startup, suggesting a much less invasive approach than Elon Musk’s Neuralink. Altman taps a leading researcher for his brain-computer ...

I would like to add the most famous problem of the interviews and different coding platforms as it comes as the daily challenge on platforms and we can only perform the merge sort on the linked list ...

A burst of experimentation followed ChatGPT's release to the public in late 2022. Now many people are integrating the newest models and custom systems into what they do all day: their work. Chefs are ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...